Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

334.35 +2.52 (+0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
These S&P500 stocks are gapping in today's session
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends. 
Via Chartmill
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Earnings To Watch: Masimo (MASI) Reports Q4 Results Tomorrow
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Integra LifeSciences (IART) Reports Earnings Tomorrow: What To Expect
Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Curious about which S&P500 stocks are generating unusual volume on Friday? Find out below.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Assessing Insulet: Insights From 6 Financial Analysts
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:PODD.
Based on Fundamental Analysis it can be said that NASDAQ:PODD is a growth stock which is not overvalued. 
Via Chartmill
$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth. 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session
Curious about the S&P500 stocks that are showing activity before the opening bell on Friday? 
Via Chartmill
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next... 
Via StockStory
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
NASDAQ:PODD—A High-Growth Stock Gearing Up for Its Next Upward Move.
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
Insulet Earnings: What To Look For From PODD
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect. 
Via StockStory
Why NASDAQ:PODD Is a Standout High-Growth Stock in a Consolidation Phase.
Based on a technical and fundamental analysis of NASDAQ:PODD we ask: Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
From Insulet Corporation
Via Business Wire
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Insulet Corporation
Via Business Wire
Looking Into Insulet's Recent Short Interest
 
Via Benzinga
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout.
Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today
 
Via Benzinga
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
Decoding 11 Analyst Evaluations For Insulet
 
Via Benzinga
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
From Insulet Corporation
Via Business Wire
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
Peering Into Insulet's Recent Short Interest
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.